OncoSec Medical, Inc. (ONCS)

Oncology Corporate Profile

Stock Performance

1.8800
-0.1100

HQ Location

9810 Summers Ridge Road, Suite 110
San Diego, CA 92121

Company Description

OncoSec Medical Inc. is a biopharmaceutical company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors. ImmunoPulse and NeoPulse therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy, and other treatment alternatives.

Website: http://www.oncosec.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
ImmunoPulseimmunotherapyMetastatic MelanomaII
ImmunoPulseimmunotherapyTriple negative Breast cancerII
ImmunoPulse (+pembrolizumab)immunotherapyMetastatic MelanomaII

View additional information on product candidates here »

Source: http://www.oncosec.com

Recent News Headlines

5/22/2017 12:18 pm

5/22/2017 12:18 pm

5/22/2017 12:18 pm

5/22/2017 12:18 pm

5/22/2017 12:18 pm

5/11/2017 12:18 am

5/11/2017 12:18 am

5/11/2017 12:18 am

5/11/2017 12:18 am

5/10/2017 12:18 am

5/10/2017 12:18 am

5/10/2017 12:18 am

5/10/2017 12:18 am

5/10/2017 12:18 am

5/8/2017 12:18 am

5/2/2017 06:18 am

5/2/2017 06:18 am

5/2/2017 06:18 am

5/2/2017 06:18 am

4/11/2017 06:17 am

OncoSec Presents Preclinical Data Demonstrating Improved Systemic Anti-Tumor Response Following Modifications to IL-12 Gene Delivery Therapy at AACR Annual Meeting

4/3/2017 12:00 pm

[PR Newswire] - SAN DIEGO, April 3, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today presented a poster titled "Intratumoral Delivery of a P2A-linked Bicistronic IL-12 Construct Leads to High Intratumoral Expression and Systemic Anti-tumor Response" (Abstract ID # 1614) at the American Association of Cancer Research (AACR) Annual Meeting, in Washington, D.C. The poster included preclinical data demonstrating the latest developments of OncoSec's gene delivery platform in a murine melanoma model. Previous studies have shown the use of immunomodulatory cytokines is effective in the regression of a wide range of tumors. Intratumoral gene electrotransfer of plasmid encoded interleukin-12 (IL-12) has shown acceptable safety and efficacy profiles in regressing tumors, both preclinically and clinically.

OncoSec to Present Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2017

3/28/2017 10:00 am

[PR Newswire] - SAN DIEGO, March 28, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will present preclinical ...

OncoSec Medical's Intratumoral Plasmid IL-12 Demonstrates Effectiveness at Enhancing Tumor Immunogenicity in Preclinical Tumor Models

3/21/2017 06:00 pm

[PR Newswire] - SAN DIEGO, March 21, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today presented a poster ...